2018-01-012024-05-14https://scholars.lib.ntu.edu.tw/handle/123456789/657737摘要：生科司107 年度業務推動共分成18 學門，分別為「生物學」1 學門、「農學」2 學門、和「醫學」15 學門，每一學門邀請一位學者擔任學門召集人。學門召集人之職掌為1) 協助專題研究計畫申請案之推動及審查， 2) 出席國際會議、海外學人來華演講與短期科學技術指導、及延攬研究人才等申請案之審查，3) 國際合作雙邊科技合作(合作領域規劃、優先合作項目建議、人員互訪交流等)、補助國內舉辦國際學術研討會、補助團隊參與國際學術組織會議及補助跨國產學合作交流及專業人才培訓等申請案之審議，4)出席學門召集人會議，協助科技部相關業務之推展，5)協助撰寫該學門研究成果年報或協助提供臨時性該學門相關學術資料，6) 辦理審查說明會、討論會、座談會或成果發表會， 7) 其他學門相關業務之諮詢、規劃與推動。8) 發掘前瞻研究主題或推動國際交流。血液免疫醫學學門涵蓋(1)血液科；(2)腫瘤科；(3)風濕免疫；及(4)感染科次學門。為一跨領域之整合學門。針對血液及腫瘤疾病、免疫及風濕疾病、各種感染症等，從基礎、轉譯到臨床研究，包括致病機轉、代謝、免疫、發炎反應及微環境與標的細胞或病原體血液免疫醫學學門在未來幾年將推動的研究方向包括以下各項：A. 血液腫瘤科的研究方向為腫瘤的致病機轉(包括基因突變、表基因的修飾，如抑癌基因與組織蛋白甲基化、微小RNA 的表現及血管新生、癌症分子變化研究)，腫瘤幹細胞研究、藥物代謝基因多形性、新抗癌藥物(特別是標靶治療)及腫瘤免疫療法如腫瘤疫苗的研發與應用、尋找新的生物標記。B. 風溼免疫的研究方向為紅斑性狼瘡及各類關節炎包括痛風與類風溼性關節炎的致病機轉與治療，探討調節T 細胞(Treg)在免疫疾病所扮演的角色，尋找各疾病的特殊標記與生物療法及中草藥的篩選與研究。C. 感染症的研究方向包括新興感染症「禽流感、流感、新流感、登革熱、猪流感、SARS、黴菌感染等」的致病機轉，台灣致病性微生物的特異性、基因體變異、抗藥性微生物與愛滋病免疫調節相關基因及Micro RNA 生合成相關基因分析及疫苗開發。以上這些血液免疫醫學雖各有專業領域，但彼此基本的研究方法與方向都有共通性，可藉由科技部生科司之學門整合，找出共同研究之主題及方向。今年也將持續推動研究朝轉譯醫學及個人化醫學方向發展，以論文發表與技術移轉並重，並與衛福部各臨床試驗中心合作推動研究員起始之臨床試驗。<br> Abstract: In 2018, the major tasks of the Department of Life Sciences, Ministry of Science and Technology will be divided into 18 subdivisions including Biology (1 subdivision), Agriculture (2 subdivisions), and Medicine (15 subdivisions) according to specialties. One scholar will be invited as a committee chairman for each subdivision. The chairman will be responsible for the following jobs: (1)to promote, direct, and review the grant application of research projects in each specific subdivision; (2) to review the application of MOST-sponsored research visits and attending international congress, to guide scientific research direction, and enrollment of outstanding research personnel; (3) to attend the joint meeting of committee chairmen to assist the promotion of major tasks of Department of Life Sciences; (4) to write the annual final reports or Year Book of research works of each specific subdivision and to provide academic consultation of specific subdivision; (5)to plan, direct, collaborate, and promote the research tasks of subdivisions of other specificities.The Division of Hematology and Immunology is composed of hematology, oncology, rheumatology, and immunology, and infectious diseases. Scientific merits include pathophysiology, diagnostics, therapeutics and prevention/control through genomics, epigenetics, proteomics, metabolomics, microbiomics, host-pathogen interaction, interaction between cell/microorganisms and microenvironment, clinical or molecular epidemiology.The major research directions of Division of Hematology and Immunology in the near future are: A. Carcinogenesis (including gene mutation, epigenetic modification e.g. methylation of suppressor genes and histone protein, microRNA expression and angiogenesis), cancer stem cell research, gene polymorphism, development and clinical application of new anti-neoplastic drugs (especially targeted therapies), and tumor vaccines. Also, we want to discover some new biomarkers of such diseases.B. Mechanism and therapies of systemic lupus erythromatosus and arthritis including gout and rheumatoid arthritis, research on regulatory T-cells (Treg), search for biomarkers of the diseases, development of biotherapy, and screening and research of Chinese herb drugs.C. New infectious disease (avian influenza, influenza, SARS, dengue hemorrhagic fever(DHF), swine flu (H1N1), and fungal infection), important pathogenic microorganisms in Taiwan, drug-resistant microorganisms and AIDS, and the development of vaccines. Although these subdivisions have their own specialties in academic interest and involved population, a common pathway in research direction and methodology will be organized after the efforts of the interdisciplinary integration by the Department of Life Sciences, Ministry of Science and Technology and focus on the translation study and personalized medicine. The performances should evaluated by either publication or technologic transfer. The PI initiated clinical study cooperated with clinic trial centers will be promote.科技部生科司血液腫瘤免疫感染醫學學門Ministry of Science and TechnologyDepartment of Life SciencesDivision of Hemato-oncologyInfection and Immunology